As previously described,7 111/209 patients were classified as having deleterious or suspected deleterious mutations present in BRCA1 and/or BRCA2 in their tumour samples and 98 patients had BRCA wild-type tumours; three further patients were known to have single exon indels in blood sample DNA but these were below the detection limit in tumour samples.7 Therefore, 95/209 patients (45.5%) were classified as having BRCA wild-type tumours. The gene discussed is BRCA2; the disease is neoplasm.